Gut-focused research peptides are studied for the GI lining, the intestinal barrier and inflammation — relevant to ulcers, leaky gut and inflammatory-bowel research.
Phase 2 trials cut celiac symptomatic days; note the Phase 3 trial was discontinued in 2022 for small effect size.
Slows gastric emptying and modulates gut-brain signalling (also the source of GI side effects).
Protects and heals GI mucosa and supports gut-barrier integrity in ulcer, colitis and fistula models.
Delays gastric emptying and modulates appetite signalling.
Orally delivered KPV reduces severity of DSS- and TNBS-induced colitis in mice.
Incretin arms slow gastric emptying and increase satiety.
⚠️ Educational research information only — not medical advice. Many peptides are research-use-only and not approved treatments. Always consult a qualified professional.